Group 1 - The core point of the article is that XuanZhu Bio-B (02575) saw its stock price rise over 5%, reaching a high of 71.9 HKD, approaching its historical peak of 72 HKD, following the inclusion of its innovative drug, Pyrocilin, in the national basic medical insurance drug list [1] - The inclusion of Pyrocilin in the insurance list is expected to enhance its affordability and accessibility for patients, thereby promoting the drug's market penetration and sales growth, which will positively impact the long-term operational development of XuanZhu Bio [1] - Pyrocilin, a new CDK2/4/6 inhibitor, has shown strong efficacy in inhibiting tumor cell proliferation and was approved by the National Medical Products Administration of China for specific types of advanced or metastatic breast cancer patients in May 2025 [1] Group 2 - Both approved indications for Pyrocilin have been included in the 2025 national basic medical insurance directory, and an application for its use in first-line treatment in combination with aromatase inhibitors is currently under review [1]
港股异动 轩竹生物-B(02575)涨超5%逼近前高 旗下创新药轩悦宁首次纳入国家基本医保药品目录